SCHEMBL5459963

SCHEMBL5459963

CC1CC1C(=O)Nc1sc2ccccc2c1C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 3/20 0.49
RAB9A P51151 5/20 0.45
NPC1 O15118 3/20 0.45
GRM1 Q13255 5/20 0.44
MAPT P10636 4/20 0.44
HPGD P15428 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LIMK1 P53667 2/20 0.44
ABCC1 P33527 2/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
MAPK1 P28482 1/20 0.42
IKBKB O14920 1/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
ALOX15 P16050 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447565 0.84 GRM1 (0.46) SMN1; SMN2LMNARAB9ANPC1GRM1
SCHEMBL5460557 0.83 FLT3 (0.51) SMN1; SMN2LMNARAB9ANPC1MAPT
SCHEMBL5165471 0.79 IKBKB (0.51) LMNARAB9ANPC1MAPTHPGD
SCHEMBL5467596 0.75 GRM1 (0.42) SMN1; SMN2LMNARAB9ANPC1GRM1
SCHEMBL5741331 0.70 ABCC1 (0.57) SMN1; SMN2LMNARAB9ANPC1MAPT
SCHEMBL5461038 0.70 FLT3 (0.70) SMN1; SMN2LMNARAB9ANPC1MAPT
SCHEMBL5449307 0.70 NPC1 (0.46) SMN1; SMN2LMNARAB9ANPC1MAPT
SCHEMBL5466117 0.69 FLT3 (0.48) SMN1; SMN2RAB9ANPC1MAPTKMT2A
SCHEMBL24426957 0.69 ABCC1 (0.45) LMNARAB9ANPC1MAPTHPGD
SCHEMBL8289668 0.69 SMN1; SMN2 (0.76) SMN1; SMN2LMNARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 SMN1; SMN2 2157/4885LMNA 3232/4885RAB9A 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.